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Abstract. The clinical and genetic features of a 43-year-old male patient with multiple endocrine
neoplasia type 1 were reported. He developed hyperparathyroidism, a GHRH-producing pancreatic
tumor, and acromegaly between 1980 and 1983. Because his pituitary gland increised in size even after
resecting the GHRH-producing pancreatic tumor, transsphenoidal hypophysectomy was performed six
years later. The pituitary contained two histologically-different adtnomai composed of somatotroph
cells and null cells. Genetic analyses revealed loss of heterozygosity on chromosome 11 in common in
the pituitary adenomas, the pancreatic endocrine tumors, and a parithyroid hyperplasia. On the other
hand, mutations of ras, p53, Gscr, and Gi2o genes were not found in theie tumixs. The loss of the tumor
suPPressor gene on chromosome 11q72-73 was involved in the formation of two pituitary adenomas,two Pancrc'atic endocrine functioning tumors, and a parathyroid hyperplasia in ihis patient, but the
tumorigenic factors in the specific endocrine organs remain to be studied
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MULTIPLE endocrine neoplasia (MEN) is charac-
terized by hyperplasia or neoplasia arising from
multiple endocrine organs and classified into types
7,24, and 28 according to the combination of af-
fected endocrine organs. Familial MEN 1 is
inherited as an autosomal dominant trait and af-
fects specific endocrine organS in the combination
of the parathyroid, the pancreatic islet and the pi-
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tuitary.
The syndrome of MEN 1 is believed to be caused
by a mutation or deletion in the MENI gene on
chromosome 77q72-73 [3]. The inactivation of the
MEN1 gene in MEN l-associated tumors can be
demonstrated by loss of heterozygosity (LOH) at
the MEN1 locus, which is localized between pyGM
and Dl15146 on 77qt2-73 [4]. Common LOH on
chromosome 11 has been found in pancreatic and
parathyroid tumors in MEN 1 patients [3-9], but
few studies have been made on the LOH in MEN
1-associated pituitary tumors. Although LOH on
chromosome 11 was not found in one MEN 1-as_
sociated pituitary adenoma by Bystrom et al. [4),
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we previously reported LOH on chromosome 11,
including loci of D11-5149, HRASI and F2 in one
familial MEN 1-associated pituitary adenoma se-
creting both GH and PRL [10]. Recently, Thakker
et al. reported another case of LOH on 11q in a
somatotroph cell adenoma from one MEN 1 pa-
tient [11].
We examined a male patient with familial MEN
1 associated with parathyroid hyperplasia, GHRH-
secreting pancreatic tumor and acromegaly. His
clinical and pathological features before and one
year after surgery were reported previously L72,
131. We also reported that LOH was detected in
pancreatic tumors from this patient [5]. The Plas-
ma GHRH level was normalized after resecting the
pancreatic tumor, but transsphenoidal hypophy-
sectomy was performed since the plasma GH level
and pituitary size gradually increased.
To clarify the relationship between an ectopic
GHRH-secreting tumor and pituitary pathology,
and to investigate the genetic abnormalities relat-
ed to tumorigenesis in specific endocrine organs,
we carried out endocrine and pathological studies
as well as genetic analyses of the tumors. We re-
port herein the results of endocrine studies,
pathology of the pituitary adenomas, common
LOH in tumors in three different endocrine organs,




A 43-yr-old man was admitted to our hospital in
September, 7992 for evaluation of his pituitary mass
and acromegaly. He was diagnosed in 1980 as
having primary hyperparathyroidism. Parathy-
roidectomy was performed three times between
1980 and 1983 and hypercalcemia was corrected.
In 1983, acromegalic features became prominent
and skull X-ray films showed an enlarged sella
turcica. In addition, abdominal CT revealed a
tumor mass in the tail of the Pancreas. His father
had Cushing's disease and primary hyperparathy-
roidism, and his younger sister had prolactinoma
and primary hyperparathyroidism. Based on the
clinical findings and family history, he was diag-
nosed as MEN 1.
Increased plasma GHRH was found in 1986, sug-
et al.
gesting an ectopic GHRH-secreting tumor in the
pancreas. Laparotomy was performed, and both a
large and a small tumor were enucleated from the
pancreas. The larger tumor weighing 30 g was
immunohistologically stained with the antibodies
for GHRH, somatostatin and calcitonin. The small-
er one was stained with those for glucagon and
pancreatic polypeptide (PP) t12, 131. After sur-
gery, the plasma GHRH level decreased to the
normal value. The plasma GH level also decreased,
but remained higher than normal. Evaluation of
the pituitary by magnetic resonance imaging (MRI)
was repeated four times and it was shown that the
pituitary mass had slowly enlarged in size.
In November, 7992, the pituitary tumor was
resected by transsphenoidal surgery. The postop-
erative course has been satisfactory.
Endocrine studies
The materials and methods for endocrine stud-
ies were previously reported in detail [12]. Plasma
GH before and after a provocative test or a suP-
pressive test was assayed by RIA [121. Plasma
GHRH was assayed as reported previously [14, 15].
Data were presented as means + SD with the num-
ber of samples shown as 'n'.
P atholo gical eaaluation
A number of tumor pieces were obtained for
pathological studies by means of a light microsco-
py and immunohistochemistry according to the
methods described previously [16J.
DNA extraction
The pituitary tumor was kept frozen at -70 "C
until analysis. DNA isolation was performed by a
standard method of phenol-chloroform extraction.
Leukocyte DNA from the patient was used as a
control to study the LOH in the tumor tissue DNA.
Genomic DNAs of the two different pituitary ade-
nomas and the parathyroid hyperplasia were
separately extracted from each tissue embedded in
paraffin as previously described [17J.
Southern blot analysis
Approximately 10 pg of DNAs extracted from
the tumors and leukocytes were digested with sev-
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eral restriction enzymes. The resulting fragments
were separated by agarose gel electrophoresis and
transferred to nitrocellulose membrane by South-
ern blotting. Hybridization, labeling of probes,
and autoradiography were performed accord-
ing to the standard procedures previously de-
scribed [5].
Detection of LOH by using microsntellite
polymorphisms
Four microsatellite loci of PYGM (CA) (GA) re-
peat [18J, D115534 [191, D115527 t20], and CD3D
[21] were used in this study. One of each oligonu-
cleotide primer pair was labeled with FAM
fluorescent dye (Perkin Elmer, Foster City, CA).
Polymerase chain reaction (PCR) was performed
with a thermal cycler (Astec, Fukuoka, ]apan) with
50 ng of genomic DNA as a template in a total
volume of 70 1t [22]. Twenty-five cycles consist-
ing of 1 min at 95 'C for denaturation, 1 min at 60
oC for annealing and 2 min at 72 "C for extension
were performed. For gel analysis, 0.5 ltl of inter-
nal lane standards (Gene Scan 2500-Rox, Perkin
Elmer), 2 1rl of PCR products and 4 pl of form-
amide were combined. Specimens were heated to
95'C for 4 min immediately prior to gel loading.
Gels consisted of 6Vo acrylamide with 8 M urea in
90 mM Tris-borate (pH 8.3) and 2 mM EDTA. Gel
electrophoresis, data collection and analysis were
performed on a Model 373A DNA sequencer with
GENESCAN 672 software (Perkin Elmer, division
of Applied Biosystems) [23J.
Screening of mutations of the p53 and rns genes by
PCR-SSCP
Mutations in exons 5 to 10 of the p53 gene, and
exons 1 and 2 of the H-, K-, N-ras genes were ana-
lyzed by PCR-SSCP as previously described [24,
251.
Detection of mutations of codons 207 and 227 of the
Csa gene by direct sequencing of genomic DNA
A pair of primers, flanking codons 207 and 227
of the Gscr gene, were used to generate a single
specific amplification product from each specimen.
The nucleotide sequence of the primers contained
at their 5' ends the additional sequence of a
universal or a reverse M13 sequence of L5'-TG-
T A A A AC G AC G G C C AG TGGTG AGATCCAT-
TGACCTCA-3' (italic: a 21M13 sequence)l and
[5' - C A AG AA AC AG CT AT G ACCCCAAGCCCA-
CAGCATCCTAC-3' (italic: an M13 reverse
sequence)l [26]. The method for direct sequencing
of the PCR products by an automated DNA se-
quencer was described previously 124,25).
Detection of mutations of codons 179 and 205 of the
Ci2a gene by direct sequencing of genomic DNA
A pair of primers (5'-CCCCCCATCCCCAGC-
TACCT-3' and 5'-TCTCACCATCTCCTCGTCCTC-
3') flanking codons 175 and 205 of G12a gene l27l
were used to obtain DNA templates for direct
sequencing. The method for conventional direct
sequencing of the PCR products with radioisotopes
was described previously t28J.
Results
Endocrine studies
In 1980, the plasma GH of the patient was al-
ready slightly increased to 7.0 + 7.2 ng/ml (n=3;
normal, <5). The plasma PRL was 3.4 ng/m/ (nor-
mal, 1.1-9.8). A paradoxical rise in plasma GH
after TRH (peak 34 ng/ml at 15 min) or oral glu-
cose load (16 ng/ml at 180 min) was observed.
Plasma GHRH in 1983, which was retrospectively
evaluated with frozen plasma samples, was in-
creased to 360 pg/rnl (normal, 70.4 ! 4.7).
Re-examination in 1985 by the TRH test confirmed
a paradoxical release of GH. The plasma GHRH
was 299 t 67 pg/ml (n=16) in 1985 to 1986 before
resecting pancreatic tumors, which was accompa-
nied by increased plasma GH (42.4 t 31.3 ng/ml,
n=16). After resection of the pancreatic tumors,
the plasma GHRH level decreased to within the
normal range, while the plasma GH level remained
high (9.8 t 3.8 nglm/, n=8). Before resection of the
pancreatic tumors, exogenous GHRH (100 pg, iv)
increased plasma GH (p"uk 205 ng/ml at 15 min),
and octreotide acetate (700 1tg, sc) suppressed GH
secretion. After resection of the pancreatic tumors,
the plasma GH increased in response to exoge-
nous GHRH, but the magnitude of the increase
was considerably smaller than that before surgery.
The response of plasma GH to TRH or glucose
was no longer observed after resection of the
SHINTANIご′α′
GHRH-secreting pancreatic tumor.
During the 3 years after resection of the pancre-
atic endocrine tumors, the pituitary mass did not
apparently increase in size in spite of the high plas-
ma GH (9.3 X2.7 ng/rr:.l, n=21) in 1986-1988. More
recently, since 1989, baseline plasma GH gradual-
ly increased (13.0 t 2.2ng/ml, n=9 in 1989, 15.0 +
5.4ng/llnl, n=26 in 7990,78.2!2.6 ng/ml, n=11 in
1991) in spite of the normal plasma GHRH, and
acromegalic features became more prominent than
before. In7992, plasma GH was 15.9 t 3.9 ng/rnl
(n=11) and plasma IGF-I was 462 ng/rnl (normal,
100-250) before the transsphenoidal surgery. In
addition, MRI showed that the pituitary mass had
gradually increased in size between 7989 and 1992
(Fig. 1). It was found only after histological anal-
ysis of the resected tumor that he had two different
pituitary adenomas. After resection of the pitu-
itary tumors, the high plasma GH reverted to
normal (2.7 ! 0.9 ng/ml, n=7).
Pnthologicnl findings
Morphological examination revealed that the re-
Fig.L. Tl-weighted MR image after gadolinium-DTPA
enhancement performed in September, 1992. This
reveals a remarkable enlargement of a pituitary
gland with heterogeneous internal intensity,
suggesting the presence of a pituitary adenoma.
sected pituitary tumors were composed of two dif-
ferent adenomas with distinct histological and
immunohistochemical features (Fig. 2). The major
characteristics of these two adenomas are summa-
rized in Table 1. One showed diffuse proliferation
of mixed eosinophilic and chromophobic cells
which contained pleomorphic nuclei and promi-
nent nucleoli. Immunohistochemical studies
showed that adenoma cells were positive for GH
among 7 adenohypophysial hormones studied.
Intracytoplasmic cytokeratin distribution was peri-
nuclear in pattern, suggesting a GH-producing
Fig.2. Microscopic aPpearance of two different pituitary
adenomas. A. Somatotroph cell adenoma.
Adenoma cells show signs of anisokaria and have
prominent nucleoli. B. Null cell adenoma. Tumor
cells with uniform and compact nuclei proliferate in
a diffuse or papillary arrangement' (hematoxylin
and eosin, x 400).
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Table 1. Histological features of two different pituitary adenomas
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positive (a few cells)
negative
negative
adenoma which lacks fibrous bodies [16]. Anoth-
er was a chromophobic adenoma composed of cells
with uniform nuclei which were smaller than
GH-producing adenomas. Focal perivascular
pseudorossette formation was noted. A few cells
were positive for an cr-subunit of glycoprotein hor-
mones, but negative for GH and cytokeratin. Thus
the second adenoma was diagnosed as a null cell
adenoma. Both adenomas were negative for PRL,
ACTH, FSHO LHpand TSHB. In the fragments of
non-tumorous adenohypophysial tissue, nearly
80% of the cells were positive for GH, but reticulin
fiber stain showed the preservation of normal ar-
chitecture. It was uncertain whether this GH-rich
portion was a GH-cell hyperplastic area or an area
where GH cells were normally abundant.
LOH on chromosome 1'L
Restriction fragment length polymorphisms of
the leukocyte- and tumor-DNAs were compared
for chromosome 11 markers. The LOH on chro-
mosome 11 in the pituitary adenomas was
identified by Southern blot analysis with DNA
probes, HRAS1, CALCA, D115151 and D715146
(Fig. 3, Table 2).
The LOH was also detected by microsatellite
polymorphism analysis on the PYGM locus (Fig. 4,
Table 2). His leukocytes on panel A showed the
amplification of two distinct clusters of fragments,
with major peaks at 186 and 776 nucleotides in
size, and the second major peaks at 184 and 774
nucleotides, respectively. The third peaks at 7g2
and 772 nucleotides were also visible. These mi-
nor peaks 2 or 4 nucleotides smaller than the major
peaks were due to polymerase skipping [23]. The
pituitary adenomas, two pancreatic tumors and
parathyroid hyperplasia on panels B, C, D and E
showed similar LOH on the PYGM locus. In addi-
tion, LOH of the loci was also observed for
D115534, D115527, and CD3D in the pituitary ade-
nomas and the GHRH-producing pancreatic tumor,
and for D1l5527 in the parathyroid hyperplasia,
but LOH in the loci of D11SS34 and D115527 was
not observed in the glucagon and pp-producing
pancreatic tumor (data not shown).
It was impossible to discern by conventional
Southern blotting analysis whether this LOH de-
rives from the somatotroph adenoma, the null cell
adenoma or both, because a very small amount of
DNA could be extracted from several pieces of tu-
mor tissue obtained by transsphenoidal surgery.
However, LOH of the loci of pyGM and D17SS27
was commonly detectable in both the somatotroph
adenoma and null cell adenoma by pCR-based mi-
crosatellite polymorphism analysis of DNA
extracted from paraffin-embedded specimens of
pituitary adenomas (data not shown).
We previously reported the loss of the common







Fig. 3. Loss of heterozygosity at loci on chromosome 11 in the pituitary adenoma and the GHRH-
producing pancreatic tumor. The DNA of two tumors and peripheral leukocytes from the
patient was digested with appropriate restriction enzymes. Lane 1 shows the digests of
DNA from peripheral leukocytes. Lanes 2 and 3 show the digests of DNAs from the
pituitary adenomas and a GHRH-producing pancreatic tumor, respectively. Numerals 1
and 2 on the left indicate the alleles observed.
Table 2. Loss of heterozygosity for informative loci in pituitary adenomas, pancreat-
ic tumors and a parathyroid hyperplasia
Tumor*
Locus Location Enzyme
3   4
HRASl  llp15 5
PTH     llP15 2-P151
CALCス  1lP15 2-P151
DllS151  1lP13
PYGル1   1lq12-q132
DllS146  1lq12-q132
DllS534  1lq13
DllS527  1lq13 5


















































*1, pituitary adenomas; 2, a GHRH-producing pancreatic tumor; 3, a glucagon and
PP-producing pancreatic tumor; 4, a parathyroid hyperplasia. O, loss of heterozygos-
ity; O, retained heterozygosity; -, not done.
HRASL markers in two pancreatic tumors from this
patient [5], but the informative polymorphic mark-
ers on the long arm of chromosome 11 were not
available at that time. In the present analysis, in-
cluding microsatellite analysis, the loci of D115146,
PYGM, D115534, D775527 and CD3D of the pa-
tient were shown to be informative, and LOH in
these loci were detected in the GHRH-producing
pancreatic tumor (Fig. 3D, Fig. 4C, and Table 2).
Because of the LOH in the loci of 11p and q both
in the GHRH-producing Pancreatic tumor and the
pituitary adenomas, extensive loss of chromosome
11 probably exists in these tumors arising from
two separate endocrine organs. Table 2 summa-
rizes the results of the genetic analysis of MEN
1-associated tumors of this patient with chromo-
some 11 markers, which demonstrate that LOH on
chromosome 11 is a common mechanism in the
monoclonal development of pancreatic endocrine
tumors, pituitary adenomas, and parathyroid hy-
perplasia in this patient with MEN 1.
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Fig.4. Flectrophoretogram display of pCR products of pyGM (cA) (GA) repeat for
leukocytes (A), the pituitary aderromas (B), the GHRH-producing pancreatic tumor(C), ttre glucagon and PP-producing pancreatic tumor (D),-ind parathyroicl
hyperplasia (E). The ordinate represents fluorescence signal inteniity and the
abscissa represents the scan number of band detection from the start of
electrophoresis. Fragment size estimates are indicated above each major peak in
panel A.
Annlyses of mutations of the rns nnd p53 genes
No mutations were detected by PCR-SSCP in
exons 1 and 2 of the F{-,K-, and N-ras genes or in
exons 5 to 10 of the p53 gene in the pituitary ade-
nomas/ two pancreatic tumors or parathyroid
hyperplasia (data not shown).
Annlyses of mutations of the Gsa nnd Gi2a genes
Direct sequencing of the Gsa gene in each of the
two pituitary adenomas (a somatotroph cell ade-
noma and a null cell adenoma), two pancreatic
tumors, and parathyroid hyperplasia revealed no






codons 179 or 205 of the Gi2cr gene were found in
these tumors (data not shown).
Discussion
Multiple specific endocrine organs are affected
in MEN 1 patients. Hyperplasia or multiple neo-
plasias are observed in the parathyroid glands and
the pancreas, but multiple pituitary tumors are ex-
tremely rare in MEN 1. Lips ef al. reported multiple
pituitary tumors in MEN 1, but did not describe
their histologies [29J. According to Scheithauer e/
al., only one out of 40 patients with MEN 1 exhib-
ited multiple microadenomas consisting of
corticotroph cell adenoma and prolactinoma [30].
In our case, two histologically-different pituitary
adenomas were found; one was a somatotroph cell
adenoma and another was a null cell adenoma.
It is noteworthy that the pituitary adenomas in
this patient became apparent 6 years after resect-
ing the GHRH-producing pancreatic tumor. In
almost all acromegalic patients with GHRH-secret-
ing tumors, including our patient, plasma GH was
either non-suppressed or paradoxically increased
,by an oral glucose load or by TRH administration.
The paradoxical responses usually reverted to nor-
mal after resection of the ectopic source of GHRH
[31], indicating that the paradoxical rise in plasma
GH was induced by the priming effect of GHRH.
In our patient, we suspected a somatotroph cell
adenoma or hyperplasia firstly because of slightly
increased plasma GH even after resecting the
GHRH-secreting pancreatic tumor, and secondly
because of the disappearance of the paradoxical
rise in plasma GH in response to TRH or glucose
after surgery. The possibility of somatotroph cell
hyperplasia was also considered, because 8 out of
9 patients with ectopic GHRH-secreting tumor were
reported to have pituitary hyperplasia [1], but one
patient was reported to have a pituitary adenoma
[32]. In transgenic mice expressing the hGHRH
gene, hyperplasia of pituitary somatotrophs, lac-
totrophs and mammosomatotrophs developed by
8 months of age, and GH- and PRl-immunoreac-
tive adenomas developed at 70-24 months of age
[33, 34]. These findings suggest that prolonged
GHRH secretion from the pancreatic tumor plays
a certain role in adenoma formation in the pitu-
itary gland.
Another important factor in adenoma formation
in the pituitary in our patient is the inactivation of
the MENI gene. The fact that LOH on chromo-
some 11 was found in pituitary adenomas as well
as pancreatic endocrine tumors and parathyroid
hyperplasia in our patient and a report of another
pituitary adenoma in an MEN 1 patient with a
GHRH-secreting pancreatic tumor [32] indicates
that the somatotroph adenoma and null cell ade-
noma in our patient arose in the common basis of
the inactivated MEN1 gene. To our knowledge,
this is the first case of common LOH on chromo-
some 11 in tumors in three separate endocrine
organs in an MEN 1 patient.
The molecular pathogenesis of MEN 1 should
also explain the lapse in time between birth and
the development of neoplasia, as well as the cellu-
lar pathology, tissue specificity, and variable
manifestations among kindred. The finding that a
similar LOH occurred even in hyperplastic pan-
creatic tissue as well as insulinoma [31 suggested
that LOH can occur even during hyperplasia and
further transformation to insulinoma was caused
by other genetic alterations. In familial polyposis
coli, colon cancer arises as a result of inherited
mutation of the APC gene and/or such somatic
mutations as the ras, and p53 genes [35]. In addi-
tion, the mutation in the Gscr gene was found in
40% of pituitary somatotroph adenomas [17], al-
though the incidence of Gsa gene mutations in
GH-secreting pituitary adenomas in ]apanese pa-
tients with acromegaly was low 136, 37), including
one pituitary adenoma in one MEN 1 patient [28],
but we detected no mutations in the ras or p53
genes in tumors from 5 MEN 1 patients including
this patient. Accordingly, genes other than the
ras, p53 or Gscr gene are presumably involved in
tumorigenic steps in MEN 1. We found a point
mutation of codon 207 of the Gsct gene in only one
pituitary adenoma, and not in the parathyroid or
pancreatic tumors of one MEN 1 patient [28], im-
plying that a point mutation of the Gsa gene might
have worked as a pituitary-specific tumorigenic
factor. However, no mutation of codon 201 or 227
of the Gsa gene was detected in pituitary adeno-
mas from our patient and five other MEN 1 pa-
tients we reported earlier [37], suggesting that this
mutation is not a major organ-specific tumorigenic
factor in MEN 1. Organ-specific gene mutations
for tumorigenesis in MEN 7, if any, should there-
fore be identified in the future, in addition to the
identification of the actual MEN1 gene and its pro-
T VヽO PITUITARY ADENOMAS IN MEN l
tein product.
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